middle.news
BCAL Takes 10% Stake in Genetic Signatures to Broaden Diagnostics Reach
10:04am on Thursday 2nd of July, 2026 AEST
•
Healthcare
Read Story
BCAL Takes 10% Stake in Genetic Signatures to Broaden Diagnostics Reach
10:04am on Thursday 2nd of July, 2026 AEST
Key Points
BCAL acquires 10.2% of Genetic Signatures for $1.39 million
Strategic move to combine cancer and infectious disease diagnostics
Genetic Signatures holds FDA clearance and international market access
Potential to leverage complementary platforms and regulatory infrastructure
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bcal Diagnostics (ASX:BDX)
OPEN ARTICLE